Today’s guest post comes from Josh Schwartz, Vice President, Medical Affairs, North America at BeOne Medicines and Matt Shaulis, General Manager, North America at BeOne Medicines.
Josh and Matt aim to raise awareness about the negative effects of insurer-imposed policies such as therapeutic substitution and step therapy. They argue that physicians have a deeper understanding of disease states and individual patient biology than insurance companies and pharmacy benefit managers (PBMs). To ensure the best outcomes, they contend that doctors—not insurers—should determine each patient’s optimal treatment plan.
Learn about BeOne Medicines, a global oncology company.
Read on for Josh and Matt’s insights.
Read more »
Source: Post feed
